Induction of the therapeutic antitumor immunity. Mice (10 mice/group) were treated by subcutaneous injection of 10 μg qVEGFR (•), mVEGFR (▪), or ALUM (▴) once a week for 4 weeks starting at day 7 after 1 × 10⁶ CT26 (A,D) or LL/2 (B,E) or Meth A cells (C,F) were introduced subcutaneously into mice. Results are expressed as mean ± SEM. Asterisks (*) indicate a significant difference in tumor volume (P < .05) between qVEGFR-treated and control groups. A significant increase in survival in qVEGFR-treated mice, compared with the control groups (P < .01, by log-rank test), was found in 3 tumor models.